Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression

Nana Sasaki, Masafumi Taniwaki|Experimental Hematology|2011

Cited by 33